MX2014006594A - Compuestos de enzimas lisosomales apuntados. - Google Patents

Compuestos de enzimas lisosomales apuntados.

Info

Publication number
MX2014006594A
MX2014006594A MX2014006594A MX2014006594A MX2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A MX 2014006594 A MX2014006594 A MX 2014006594A
Authority
MX
Mexico
Prior art keywords
compounds
lysosomal enzyme
compound
targeting moiety
enzyme compounds
Prior art date
Application number
MX2014006594A
Other languages
English (en)
Inventor
Dominique Boivin
Jean-Paul Castaigne
Michel Demeule
Sasmita Tripathy
Jean-Christophe Currie
Simon Lord-Dufour
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of MX2014006594A publication Critical patent/MX2014006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Abstract

La presente invención está relacionada con un compuesto que incluye un enzima lisosomal y una fracción que apunta, por ejemplo, donde el compuesto es una proteína de fusión que incluye una 2-sulfatasa iduronato y Angiopep-2. En ciertas formas de realización, estos compuestos, debido a la presencia de la fracción que apunta, pueden cruzar la barrera hematoencefálica o acumularse en el lisosoma de manera más efectiva que la enzima sola. La invención también se refiere a métodos para tratar desórdenes del almacenamiento lisosomal (v. gr., mucopolisacarido-sis tipo II) usando tales compuestos.
MX2014006594A 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados. MX2014006594A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161565764P 2011-12-01 2011-12-01
US201261596515P 2012-02-08 2012-02-08
US201261660564P 2012-06-15 2012-06-15
PCT/CA2012/050867 WO2013078564A2 (en) 2011-12-01 2012-11-30 Targeted lysosomal enzyme compounds

Publications (1)

Publication Number Publication Date
MX2014006594A true MX2014006594A (es) 2015-09-16

Family

ID=48536183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006594A MX2014006594A (es) 2011-12-01 2012-11-30 Compuestos de enzimas lisosomales apuntados.

Country Status (11)

Country Link
US (1) US20150037311A1 (es)
EP (1) EP2785838A4 (es)
JP (1) JP2015505824A (es)
CN (1) CN104145015A (es)
AU (1) AU2012344702A1 (es)
BR (1) BR112014013161A2 (es)
CA (1) CA2857567A1 (es)
HK (2) HK1200189A1 (es)
MX (1) MX2014006594A (es)
RU (1) RU2014126484A (es)
WO (1) WO2013078564A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583562B1 (en) 2003-01-06 2011-06-15 Angiochem Inc. Angiopep-1, related compounds, and uses thereof
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8710013B2 (en) 2008-04-18 2014-04-29 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
EP2370471B1 (en) 2008-12-05 2017-02-22 Angiochem Inc. Neurotensin conjugate and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (es) 2009-07-02 2015-05-01 Angiochem Inc
AU2013273894A1 (en) * 2012-06-15 2015-02-05 Angiochem Inc. Targeted iduronidase compounds
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MX2015012873A (es) * 2013-03-15 2016-02-03 Amicus Therapeutics Inc Reticuladores quimicos.
WO2014194428A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted heparan sulfatase compounds
JP6739333B2 (ja) * 2013-07-11 2020-08-12 ノバルティス アーゲー 部位特異的化学酵素的タンパク質修飾
CN112851790A (zh) * 2014-06-23 2021-05-28 诺华股份有限公司 位点特异性蛋白质修饰
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
PL1877099T3 (pl) * 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
EP2235175A4 (en) * 2007-12-20 2012-04-25 Angiochem Inc POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF
EP2370471B1 (en) * 2008-12-05 2017-02-22 Angiochem Inc. Neurotensin conjugate and uses thereof
WO2010063124A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
WO2011041897A1 (en) * 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
CN104136606A (zh) * 2011-12-01 2014-11-05 安吉奥开米公司 靶向的艾杜糖-2-硫酸酯酶化合物

Also Published As

Publication number Publication date
CA2857567A1 (en) 2013-06-06
JP2015505824A (ja) 2015-02-26
US20150037311A1 (en) 2015-02-05
CN104145015A (zh) 2014-11-12
EP2785838A2 (en) 2014-10-08
WO2013078564A3 (en) 2013-09-06
AU2012344702A1 (en) 2014-06-19
HK1200189A1 (en) 2015-07-31
HK1204002A1 (en) 2015-11-06
RU2014126484A (ru) 2016-02-10
WO2013078564A2 (en) 2013-06-06
EP2785838A4 (en) 2015-07-01
BR112014013161A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
MX2014006594A (es) Compuestos de enzimas lisosomales apuntados.
WO2013078562A3 (en) Targeted iduronate-2-sulfatase compounds
MX2014015551A (es) Compuestos iduronidasa apuntados.
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
WO2010148253A3 (en) Formulations for lysosomal enzymes
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
MX2019009191A (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
MA35023B1 (fr) Inhibiteurs de la glucosylcéramide synthase
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
EA201490036A1 (ru) Соединения, ингибирующие металлоферменты
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MX347808B (es) Variantes de plasminogeno y plasmina.
IN2014CN02584A (es)
WO2011163648A8 (en) Cns delivery of therapeutic agents
MX337248B (es) Variantes de plasminogeno y plasmina.
WO2013026740A3 (en) Methods and means to modify a plant genome
WO2011163652A3 (en) Treatment of sanfilippo syndrome type b
BR112014013963A8 (pt) compostos inibidores de metaloenzimas
MX2013000321A (es) Suministro al sistema nervioso central de agentes terapeuticos.
WO2013091897A8 (en) Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
MX349801B (es) Sustratos de enzimas de ácido nucleico.
WO2012058529A3 (en) Metalloenzyme inhibitor compounds